Article
Clinical Neurology
Johanna Balslev Andersen, Finn Sellebjerg, Melinda Magyari
Summary: This study found no increased association of adverse pregnancy outcomes in newborns with fetal exposure to disease-modifying drugs (DMDs) when compared with either DMD-unexposed pregnancies or the general population.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Immunology
Undine Proschmann, Rocco Haase, Hernan Inojosa, Katja Akgun, Tjalf Ziemssen
Summary: This study observed women treated with natalizumab during pregnancy and lactation, finding that most patients did not experience disease activity during gestation and postpartum. Natalizumab concentration in breastmilk was low but detectable sNfL levels were present in most samples.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Fabien Rollot, Justine Couturier, Romain Casey, Sandrine Wiertlewski, Marc Debouverie, Jean Pelletier, Jerome De Seze, Pierre Labauge, Aurelie Ruet, Eric Thouvenot, Jonathan Ciron, Eric Berger, Olivier Gout, Pierre Clavelou, Bruno Stankoff, Olivier Casez, Bertrand Bourre, Helene Zephir, Thibault Moreau, Christine Lebrun-Frenay, Elisabeth Maillart, Gilles Edan, Jean-Philippe Neau, Alexis Montcuquet, Philippe Cabre, Jean-Philippe Camdessanche, Gilles Defer, Haifa Ben Nasr, Aude Maurousset, Karolina Hankiewicz, Corinne Pottier, Emmanuelle Leray, Sandra Vukusic, David-Axel Laplaud
Summary: This study compared the effectiveness of NTZ and anti-CD20 as a switch for FNG in highly active RRMS patients in France. The results showed no difference between the two treatments regarding the first occurrence of relapse, EDSS worsening, and MRI activity. However, there was a higher risk of treatment discontinuation with NTZ compared to anti-CD20.
Article
Clinical Neurology
Marina Boziki, Christos Bakirtzis, Virginia Giantzi, Styliani-Aggeliki Sintila, Stylianos Kallivoulos, Theodora Afrantou, Ioannis Nikolaidis, Panagiotis Ioannidis, Theodoros Karapanayiotides, Ioanna Koutroulou, Dimitrios Parissis, Nikolaos Grigoriadis
Summary: The study results suggest that NTZ may be superior to FTY in preventing relapses and MRI activity, with NTZ-treated patients potentially achieving long-term clinical and radiological remission.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Chao Zhu, Zhen Zhou, Izanne Roos, Daniel Merlo, Tomas Kalincik, Serkan Ozakbas, Olga Skibina, Jens Kuhle, Suzanne Hodgkinson, Cavit Boz, Raed Alroughani, Jeannette Lechner-Scott, Michael Barnett, Guillermo Izquierdo, Alexandre Prat, Dana Horakova, Eva Kubala Havrdova, Richard Macdonell, Francesco Patti, Samia Joseph Khoury, Mark Slee, Rana Karabudak, Marco Onofrj, Vincent Van Pesch, Julie Prevost, Mastura Monif, Vilija Jokubaitis, Anneke van der Walt, Helmut Butzkueven
Summary: Ocrelizumab and natalizumab are more effective than cladribine in reducing relapses in patients with relapsing-remitting multiple sclerosis switching from fingolimod. Additional observation time is needed to determine if the statistical difference in annualized relapse rate (ARR) results in long-term disability differences.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Clinical Neurology
Kevin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, Claude Gaultier, Sylvie Courtois, Nicolas Collongues, Jerome de Seze
Summary: This study compared the effectiveness of ocrelizumab and fingolimod after natalizumab cessation. The results showed that ocrelizumab had a significantly lower relapse rate at 1 year compared to fingolimod.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Clara G. Chisari, Simona Toscano, Sebastiano Arena, Chiara Finocchiaro, Arturo Montineri, Francesco Patti
Summary: This case series presents the clinical outcomes of MS patients receiving NTZ during active COVID-19 infection. Most patients were asymptomatic, with one experiencing a slightly worse COVID-19 course. None required O2 therapy or intensive care, and no neurological complications were observed.
Article
Clinical Neurology
Alyssa A. Toorop, Theo Rispens, Eva M. M. Strijbis, Bob W. van Oosten, Brigit A. de Jong, Bernard M. J. Uitdehaag, Joep Killestein, Zoe L. E. van Kempen
Summary: In pregnant women with very active multiple sclerosis, Natalizumab concentrations gradually decrease during pregnancy, especially in patients with low initial trough concentrations or extended interval dosing. After delivery, Natalizumab concentrations return to pre-pregnancy levels, and patients remain clinically and radiologically stable. MS neurologists should be aware of these changes in drug concentrations during pregnancy.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Doriana Landi, Gaia Cola, Vittorio Mantero, Roberto Balgera, Lucia Moiola, Agostino Nozzolillo, Vincenzo Dattola, Leonardo Sinisi, Roberta Fantozzi, Sonia Di Lemme, Diego Centonze, Giorgia Mataluni, Carolina Gabri Nicoletti, Girolama Alessandra Marfia
Summary: This study reports the clinical outcomes of 18 patients with multiple sclerosis (MS) receiving retreatment with Natalizumab (NTZ) during confirmed SARS-CoV-2 infection. The results show that redosing NTZ does not lead to worsening of infection or delay in recovery, supporting the safety of NTZ retreatment in this situation.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Alyssa A. Toorop, Zoe L. E. van Kempen, Maurice Steenhuis, Jessica Nielsen, L. G. F. Sinnige, Gert van Dijk, Christiaan M. Roosendaal, Edo P. J. Arnoldus, Elske Hoitsma, Birgit Lissenberg-Witte, Brigit A. de Jong, Bob W. van Oosten, Eva M. M. Strijbis, Bernard M. J. Uitdehaag, Theo Rispens, Joep Killestein
Summary: The study evaluated the change in natalizumab trough drug levels when switching from intravenous to subcutaneous administration. It was found that the drug levels were on average 55% lower with subcutaneous administration, leading to very low levels in some patients. Monitoring of trough drug levels is advised when switching to subcutaneous administration in patients with low intravenous drug levels, higher body mass index, or extended treatment intervals.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Gabriel Valero-Lopez, Jorge Millan-Pascual, Francisca Iniesta-Martinez, Juan L. Delgado-Marin, Judith Jimenez-Veiga, Ana B. Tejero-Martin, Adelaida Leon-Hernandez, Joaquin Zamarro-Parra, Ana Morales-Ortiz, Jose E. Meca-Lallana
Summary: This study retrospectively analyzed the use of natalizumab in pregnant women with highly active multiple sclerosis (HAMS). The implementation of the NAP-30 protocol allowed for the continuation of natalizumab treatment during pregnancy, with positive clinical and radiological outcomes and good maternal-fetal safety profile.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Virology
Simone Agostini, Roberta Mancuso, Andrea Saul Costa, Domenico Caputo, Mario Clerici
Summary: The detection of miR-J1-5p in urine of MS patients treated with Natalizumab could potentially serve as a biomarker to monitor JCPyV infection and better identify the risk of developing PML. The study found miR-J1-5p in the urine of 28% of patients, even in some cases where JCPyV DNA was not detected in urine or blood. This suggests that miR-J1-5p measurement could be valuable in assessing PML risk in Natalizumab-treated MS patients.
Article
Medicine, General & Internal
Ranjani Ganapathy Subramanian, Dana Horakova, Manuela Vaneckova, Balazs Lorincz, Jan Krasensky, Eva Kubala Havrdova, Tomas Uher
Summary: The study found that natalizumab treatment can reduce inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients, decrease the levels of white blood cells and proteins, as well as the number of oligoclonal bands in the cerebrospinal fluid. Additionally, the baseline IgM index was found to predict brain volume loss during natalizumab treatment.
Article
Clinical Neurology
Marco Puthenparampil, Marta Gaggiola, Alessandro Miscioscia, Valentina Annamaria Mauceri, Federica De Napoli, Giovanni Zanotelli, Mariagiulia Anglani, Margherita Nosadini, Stefano Sartori, Paola Perini, Francesca Rinaldi, Paolo Gallo
Summary: This study evaluated the efficacy and safety of alemtuzumab (ALZ) in pediatric-onset multiple sclerosis (POMS) and adult-onset multiple sclerosis (AOMS) patients undergoing treatment switch. The results showed that ALZ was more effective in AOMS patients compared to POMS patients after switching from natalizumab (NTZ). However, these findings may underestimate the effectiveness of ALZ in POMS patients.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Clinical Neurology
Alyssa A. Toorop, Zoe Y. G. J. van Lierop, Liza M. Y. Gelissen, Elske Hoitsma, Esther M. P. E. Zeinstra, Luuk C. van Rooij, Caspar E. P. van Munster, Anke Vennegoor, Jop P. Mostert, Beatrijs H. A. Wokke, Nynke F. Kalkers, Erwin L. J. Hoogervorst, Jeroen J. J. van Eijk, Christiaan M. Roosendaal, Jolijn J. Kragt, Marijke Eurelings, Jessie van Genugten, Jessica Nielsen, Lgf Sinnige, Mark E. Kloosterziel, Edo P. J. Arnoldus, Gert W. van Dijk, Willem H. Bouvy, Mark H. J. Wessels, Lynn Boonkamp, Eva M. M. Strijbis, Bob W. van Oosten, Brigit A. De Jong, Birgit Lissenberg-Witte, Frederik Barkhof, Bastiaan Moraal, Charlotte E. Teunissen, Theo Rispens, Bernard M. J. Uitdehaag, Joep Killestein, Zoe L. E. van Kempen
Summary: Personalized extended interval dosing of natalizumab effectively controls disease activity in multiple sclerosis and can safely extend treatment intervals through therapeutic drug monitoring.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)